NCT01591161View on ClinicalTrials.gov

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

369

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

July 31, 2013

Conditions
CataractInflammationSurgery
Interventions
DRUG

Mapracorat

1 drop of study medication into the study eye QID for 14 days

DRUG

Placebo

1 drop of vehicle into the study eye QID for 14 days.

Trial Locations (1)

14609

Bausch & Lomb Incorporated, Rochester

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01591161 - Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | Biotech Hunter | Biotech Hunter